Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes

Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. Diabetes is a global epidemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy; very low levels of blood glucose can lead to cognitive decline, cardiovascular events and even death.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news